NCT03213353View on ClinicalTrials.gov

A Bioequivalence Study Between Two Brands of Medications to Treat Cough & Cold Symptoms

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

July 3, 2017

Primary Completion Date

July 17, 2017

Study Completion Date

July 17, 2017

Conditions
BioequivalenceHealthy Volunteers
Interventions
DRUG

Tablet paracetamol, guaifenesin and phenylephrine HCL

Each subject will receive two tablets, each containing 250 mg paracetamol, 100 mg guaifenesin, and 5 mg phenylephrine hydrochloride

DRUG

Vicks Active SymptoMax Plus powder for oral solution

Each subject will receive one sachet, containing 500 mg paracetamol, 200 mg guaifenesin, and 10 mg phenylephrine hydrochloride

Trial Locations (1)

196143

Scientific Research center Eco-Safety LLC, Saint Petersburg

All Listed Sponsors
lead

Johnson & Johnson Consumer and Personal Products Worldwide

INDUSTRY

NCT03213353 - A Bioequivalence Study Between Two Brands of Medications to Treat Cough & Cold Symptoms | Biotech Hunter | Biotech Hunter